Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy

Huang, Pingsheng; Wang, Xiaoli; Liang, Xiaoyu; Yang, Jing; Zhang, Chuangnian; Kong, Deling; Wang, Weiwei

doi:10.1016/j.actbio.2018.12.028

Cited by 160 publications

(94 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…504 Another example are DNA nanohydrogels based on aptamers which are now developed for gene therapy, 505 virus-mimetic gels are used for specific drug delivery, 278 and hydrogels are suggested for use in immunotherapy. 506 Besides hydrogels which only carry one type of drug also multimodality systems can be obtained. Such systems often incorporate several different therapeutic methods.…”

Section: Discussionmentioning

confidence: 99%

Hydrogels: soft matters in photomedicine

Khurana

Gierlich

Meindl

et al. 2019

Photochem Photobiol Sci

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Hydrogels: soft matters in photomedicine

Khurana

Gierlich

Meindl

et al. 2019

Photochem Photobiol Sci

View full text Add to dashboard Cite

show abstract

“…DDS have gained much attention for the treatment of cancer. Advantages of DDS include their ability to profoundly alter and improve drug pharmacokinetics, provide targeted drug delivery, and therefore alleviate TRAEs whilst enhancing therapeutic outcomes [ 125 , 126 , 127 , 128 ]. The three main DDS discussed here are liposomes, polymers and hydrogels ( Table 3 ) [ 14 , 123 , 124 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 ].…”

Section: Future Directionsmentioning

confidence: 99%

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy

Aval

Pease

Sharma

et al. 2020

JCM

160

130

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have been effective in only a small subset of patients and a principal mechanism underlying immune-refractoriness is a ‘cold’ tumour microenvironment, that is, lack of a T-cell-rich, spontaneously inflamed phenotype. As such, there is a demand to develop strategies to transform the tumour milieu of non-responsive patients to one supporting T-cell-based inflammation. The cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway is a fundamental regulator of innate immune sensing of cancer, with potential to enhance tumour rejection through the induction of a pro-inflammatory response dominated by Type I interferons. Recognition of these positive immune-modulatory properties has rapidly elevated the STING pathway as a putative target for immunotherapy, leading to a myriad of preclinical and clinical studies assessing natural and synthetic cyclic dinucleotides and non-nucleotidyl STING agonists. Despite pre-clinical evidence of efficacy, clinical translation has resulted into disappointingly modest efficacy. Poor pharmacokinetic and physiochemical properties of cyclic dinucleotides are key barriers to the development of STING agonists, most of which require intra-tumoral dosing. Development of systemically administered non-nucleotidyl STING agonists, or conjugation with liposomes, polymers and hydrogels may overcome pharmacokinetic limitations and improve drug delivery. In this review, we summarise the body of evidence supporting a synergistic role of STING agonists with currently approved ICI therapies and discuss whether, despite the numerous obstacles encountered to date, the clinical development of STING agonist as novel anti-cancer therapeutics may still hold the promise of broadening the reach of cancer immunotherapy.

show abstract

“…Targeted drug delivery has gained considerable attention in recent years, especially for cancer treatment 1. Likewise, cutting‐edge nano‐ and microparticle drug carriers have been developed to achieve controlled drug release, targeted delivery, and minimal side effects during systemic administration 2,3. However, despite encouraging results in preclinical models of solid tumors with leaky vasculature, these novel drug delivery systems have shown unsatisfactory therapeutic outcomes in clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Real‐Time Imaging Tracking of Engineered Macrophages as Ultrasound‐Triggered Cell Bombs for Cancer Treatment

Tian

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Cell‐based drug delivery systems are a promising platform for tumor‐targeted therapy due to their high drug‐loading capacities and inherent tumor‐homing abilities. However, the real‐time tracking of these carrier cells and controlled release of the encapsulated drugs are still challenging. Here, ultrasound‐activatable cell bombs are developed by encapsulating doxorubicin (DOX) and phase transformable perfluoropentane (PFP) into hollow mesoporous organosilica nanoparticles (HMONs) to prepare DOX/PFP‐loaded HMONs (DPH), followed by internalization into macrophages (RAW 264.7 cells). The resulting cell bombs (DPH‐RAWs) can maintain viability and actively home to the tumor. Especially, their migration can be tracked in real time using ultrasound due to the vaporization of a small portion of PFP during cell incubation at 37 °C. After accumulation at the tumor site, the further vaporization of remaining PFP can be triggered by a short‐pulsed high intensity focused ultrasound (HIFU) sonication, resulting in the generation of several large microbubbles, which destroys DPH‐RAWs and allows drug release out of these cells. The DPH‐RAWs combined with short‐pulsed HIFU sonication significantly inhibit tumor growth and prolong survival of tumor‐bearing mice. In conclusion, this study provides a new approach to cell‐based drug delivery systems for real‐time tracking of their migration and targeted cancer treatment.

show abstract

Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy

Cited by 160 publications

References 134 publications

Hydrogels: soft matters in photomedicine

Hydrogels: soft matters in photomedicine

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy

Real‐Time Imaging Tracking of Engineered Macrophages as Ultrasound‐Triggered Cell Bombs for Cancer Treatment

Contact Info

Product

Resources

About